COVID-19 treatment News
-
Presentation at ECCMID
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, presented the sub-group analysis from its Phase 2, SG016 study on Saturday 23 April in an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held in Lisbon, ...
-
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. Those who took both drugs had a median time to recovery of seven ...
By Benevolent
-
Bio-production: Fab’entech presents its new industrial site
Fab'entech, a French biotech specialised in the development and production of polyclonal antibodies, presents its new industrial site located in Saint-Priest, to the south-east of Lyon. The 1,000 m2 production site is now operational and will give Fab'entech the capacity to manufacture all of its innovations (biodefense and anti-COVID-19 programme: FabenCOV) in France. Close-up of this new site, ...
By Fab’entech
-
Alveo Technologies Announces CE Mark for its be.well™ COVID-19 Flex Test
Alveo Technologies, Inc. (Alveo) announced today that it has received its first regulatory approval with the CE (Conformité Européenne) Mark for its be.well COVID-19 Flex Test. The be.well platform is a molecular test based on an isothermal nucleic acid amplification process, and has a real-time healthcare data application program to help accelerate time to COVID-19 treatment and ...
-
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
VANCOUVER, British Columbia, – AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Lilly. The U.S. government will accept the ...
-
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for ...
-
In Response to Coronavirus, Guild Associates Announces RSU Series
While the world is rightly focused on the limiting the transmission of the Covid-19 virus and treatment of the inflicted, consideration must also be made to overwhelming the mortuary industry capacity. Lack of adequate capacity for safe and respectful storage of human remains could result in further transmission of the virus during the grieving process. Guild Associates’ experience ...
-
U.S. District Court Issues Temporary Restraining Order for Silver Products Fraudulently Promoted as a Treatment for COVID-19
On April 29, 2020, the U.S. District Court for the District of Utah issued a temporary restraining order (TRO) to halt the sale of a fraudulent coronavirus (COVID-19) treatment. The U.S. Department of Justice (DOJ) announced the court’s decision in an effort to halt the sale of silver products fraudulently claimed to prevent and cure COVID-19. DOJ filed a civil complaint on April 27, ...
-
ExThera Medical Partners with Predicate Healthcare Performance Group to Expand Reach of Proven COVID-19 Treatment
MARTINEZ, Calif. – ExThera Medical and Predicate Healthcare Performance Group (Predicate HPG) have entered into a commercial partnership agreement in the United States for ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). “In Predicate HPG’s ongoing efforts to deliver evidence-based, technology-enabled care to every patient, we are pleased to ...
-
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19. Insilico's PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico's AI platform. The compound can be efficiently ...
-
DOD to Fund a Multi-Center Randomized Clinical Trial of COVID-19 Treatment with ExThera’s Seraph 100 Blood Filter
After encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the United States and fourteen other hospitals in Europe, the Department of Defense has selected the Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) as one of its main interventions in a pivotal, US-based randomized controlled trial. Financial support for the ...
-
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...
By Benevolent
-
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to ...
-
ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Seraph 100 used for Blood Purification and Pathogen Reduction in Sepsis and COVID-19 Treatments MARTINEZ, Calif. – ExThera Medical and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExThera’s Seraph® 100 Microbind® Affinity Blood Filter in Mexico. In 2021, ExThera ...
-
Fab’entech is launching an immunotherapy programme against COVID-19
Fab’entech, a Lyon-based biopharmaceutical company specialised in immunotherapies for emergency situations, is today announcing the launch of a programme to develop an immunotherapy treatment against COVID-19. The treatment will be indicated in severely ill patients requiring respiratory assistance. The clinical trials are expected to begin in humans in 2021. In order to meet the new ...
By Fab’entech
-
Beyond Air Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced ...
-
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in ...
-
World Health Organization Panel Strongly Recommends The Use Of Baricitinib To Treat Hospitalised Patients With COVID-19
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able to rapidly pinpoint ...
By Benevolent
-
Thermo Fisher Scientific`s Response to COVID-19 Continues to Expand to Support Development and Production of Therapeutics and Vaccines
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects ...
-
Nanologica to Participate in Partnering Against COVID-19
Nanologica will participate in the virtual partnering event Partnering Against COVID-19 on May 4 – 6. The aim of the event is to support the fight against COVID-19 and to accelerate global collaboration. Participating parties will consist of organizations working with solutions for COVID-19 testing, treatment and prevention. “In these difficult times, we are excited to take part ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you